GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

IDE397   Click here for help

GtoPdb Ligand ID: 14409

Synonyms: compound 167 [US11046691] | GSK-4362676 | GSK4362676 | IDE-397
Compound class: Synthetic organic
Comment: IDE397 is a methionine adenosyltransferase 2A (MAT2A) inhibitor [1-3]. It was designed to target the MAT2A-SAM axis and induce synthetic lethal effects in MTAP-deleted tumours.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 71.05
Molecular weight 340.69
XLogP 1.03
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC(=C(C=C1)N2C3=C(C=CC(=N3)C(F)(F)F)C(=NC2=O)N)Cl
Isomeric SMILES C1=CC=C(C(=C1)N2C3=C(C=CC(=N3)C(F)(F)F)C(=NC2=O)N)Cl
InChI InChI=1S/C14H8ClF3N4O/c15-8-3-1-2-4-9(8)22-12-7(11(19)21-13(22)23)5-6-10(20-12)14(16,17)18/h1-6H,(H2,19,21,23)
InChI Key BVNKURJMNQNVAO-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
IDE397 was progressed as a clinical candidate for the treatment of MTAP-deleted solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04794699 Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion Phase 1 Interventional IDEAYA Biosciences
NCT05975073 A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors Phase 1/Phase 2 Interventional Amgen
NCT07277413 A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors Phase 1 Interventional IDEAYA Biosciences